| Summary: | Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are both anti-neutrophil cytoplasm antibody (ANCA)- associated vasculitis (AAV) variants. The most common severe manifestation of both GPA and MPA is associated with pauci- immune necrotising glomerulonephritis, which left untreated progresses to end-stage renal disease. Other symptoms of GPA and MPA are heterogeneous, involve multiple systems, and tools such as the Birmingham Vasculitis Activity Score (BVAS) can assist in defining disease remissions, relapses, and flares. The purpose of this report is to retrieve and review existing evidence for the clinical effectiveness, safety, and cost-effectiveness of rituximab (RTX) treatments, beyond the initial course, for the maintenance of remission in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients
|
|---|